MARKET

ARVN

ARVN

Arvinas
NASDAQ
11.65
-0.19
-1.56%
After Hours: 11.67 +0.02 +0.17% 18:49 02/13 EST
OPEN
12.20
PREV CLOSE
11.84
HIGH
12.50
LOW
11.56
VOLUME
834.46K
TURNOVER
--
52 WEEK HIGH
20.38
52 WEEK LOW
5.90
MARKET CAP
748.21M
P/E (TTM)
-14.4738
1D
5D
1M
3M
1Y
5Y
1D
Arvinas Names Randy Teel President, CEO
Dow Jones · 1d ago
Arvinas appoints new president and CEO; leadership transition announced
Seeking Alpha · 1d ago
Arvinas Announces Leadership Transition and New CEO Appointment
TipRanks · 1d ago
Arvinas appoints Randy Teel as President, CEO, director
TipRanks · 1d ago
Arvinas Sets CEO Base Salary at $680,000 With Equity and Bonus Package
Reuters · 1d ago
*Arvinas: Teel Succeeds John Houston, Who Is Retiring as Pres, CEO and Board Chair >ARVN
Dow Jones · 1d ago
*Arvinas Announces Appointment of Randy Teel as Pres, CEO and Director >ARVN
Dow Jones · 1d ago
Arvinas Appoints Randy Teel as President and CEO
Reuters · 1d ago
More
About ARVN
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.

Webull offers Arvinas Inc stock information, including NASDAQ: ARVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARVN stock methods without spending real money on the virtual paper trading platform.